Veru

Yahoo Finance • last month

Veru Announces Proposed Public Offering

MIAMI, FL, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, announced t... Full story

Yahoo Finance • 2 months ago

Onconetix announces financing through private placement, debt settlement

Onconetix (ONCO) announced the September 22, 2025 signing and closing of a private placement of shares of the Company’s Series D Convertible Preferred Stock, $0.00001 par value, and warrants to purchase up to an aggregate of 4,362,827 shar... Full story

Yahoo Finance • 2 months ago

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today anno... Full story

Yahoo Finance • 4 months ago

Veru outlines Phase III plans for enobosarm and signals upcoming FDA clarity on lean mass preservation in obesity treatment

Earnings Call Insights: Veru Inc. (VERU) Q3 2025 MANAGEMENT VIEW * CEO Mitchell S. Steiner reported that Veru is focusing its late clinical-stage biopharmaceutical efforts on cardiometabolic and inflammatory diseases, emphasizing two c... Full story

Yahoo Finance • 4 months ago

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

--Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal side effects compared to semaglutide alone-... Full story

Yahoo Finance • 4 months ago

Veru Q3 2025 Earnings Preview

* Veru (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]) is scheduled to announce Q3 earnings results on Tuesday, August 12th, before market open. * The consensus EPS Estimate is -$0.50 [https://seekingalpha.com/symbol/VERU/earnings... Full story

Yahoo Finance • 4 months ago

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

MIAMI, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced... Full story

Yahoo Finance • 4 months ago

Veru announces 1-for-10 reverse stock split

* Veru (NASDAQ:VERU [https://seekingalpha.com/symbol/VERU]) on Wednesday announced a reverse stock split at a ratio of 1-for-10, effective August 11, 2025. * At the effective time, all outstanding stock options, stock appreciation righ... Full story

Yahoo Finance • 4 months ago

Veru Announces Reverse Stock Split

MIAMI, FL, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today annou... Full story

Yahoo Finance • 4 months ago

Veru to Report Fiscal 2025 Third Quarter Financial Results on August 12th

MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced... Full story

Yahoo Finance • 4 months ago

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today annou... Full story

Yahoo Finance • 5 months ago

InvestingPro's Fair Value model captures 67% upside in Veru shares

When InvestingPro’s Fair Value models identified (NASDAQ:VERU) as significantly undervalued in January 2024, the healthcare company’s stock was trading at just $0.41. Today, that analysis has proven remarkably accurate, with shares deliver... Full story

Yahoo Finance • 5 months ago

Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation

--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly... Full story

Yahoo Finance • 6 months ago

Veru to Participate in the Virtual BTIG Obesity Health Forum

MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today annou... Full story

Yahoo Finance • 6 months ago

Tootsie Roll among names set to join Russell 3000 Index, Growgeneration, Veru set to leave

[Financial Stock Market Technology] koto_feja FTSE Russell has released a preliminary list of companies [https://www.lseg.com/content/dam/ftse-russell/en_us/documents/other/ru3000-additions-20250523.pdf]set to join or leave the Russell 30... Full story

Yahoo Finance • 6 months ago

Beyond Meat, Plby among consumer staple names set to join Russell Microcap Index, Veru, Vitals Farms to leave

[Financial Stock Market Technology] koto_feja FTSE Russell released a preliminary list of companies set to join or leave the Russell Microcap Index as part of its 2025 annual reconstitution. The consumer staple companies set to join the... Full story

Yahoo Finance • 6 months ago

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial efficacy and safety data, enobosarm 3... Full story

Yahoo Finance • 7 months ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today anno... Full story

Yahoo Finance • 8 months ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today anno... Full story

Yahoo Finance • 10 months ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical... Full story